GenHenn Venture

Sonavex develops imaging technologies for vascular and surgical care, employing ultrasound to detect postoperative blood clots at the point of care and to measure intravascular flow metrics for timely decision making. It also develops bioresorbable, echogenic devices to mark at-risk vessels and to collect data on arteriovenous fistula flow, diameter, and depth at dialysis clinics to assess maturation and anticipate future complications. Based in Baltimore, Maryland, Sonavex focuses on delivering data-driven visualization of vessel health to improve surgical and dialysis patient outcomes.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

Prana Thoracic, Inc., based in Houston, is a medical device startup focused on developing innovative solutions for the early intervention of lung cancer, the leading cause of cancer-related deaths in the United States. The company aims to address the critical challenges in lung cancer screening and diagnosis, where only a small percentage of cases are detected at an early stage. Prana Thoracic's advanced electrosurgical instrument utilizes bipolar radiofrequency energy to perform minimally invasive procedures, enabling physicians to capture and diagnose small, hard-to-reach lung nodules while reducing the risk of complications. By enhancing the tools available for surgical oncology in lung cancer, Prana Thoracic seeks to improve patient outcomes and capitalize on recent advancements in screening guidelines, ensuring early intervention opportunities are not missed.

MEND is a life sciences company dedicated to improving health outcomes through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that aid in healing from injuries, surgeries, and illness, as well as enhancing physical performance and addressing the challenges of aging. MEND's innovations have gained acceptance in various sectors, including hospitals, health systems, professional sports teams across major leagues, and elite military forces in the United States. The company's commitment to ongoing research and development positions it as a key player in the field of clinical nutritional products, aimed at enabling caregivers to support patients in achieving optimal health and recovery.

Diligent Pharma is a platform that streamlines the selection and qualification of clinical trial service providers. It simplifies and accelerates the process for identification, selection, and qualification of clinical trial service providers. Trial sponsors can access standardized Vendor Qualification Assessment (VQA) reports and Request for Information (RFI) information from Diligent. As a result, they will require significantly less time and money to qualify a GCP vendor before beginning a clinical investigation.

Xenocor designs and develops single-use, fog-free, high-definition laparoscopic imaging equipment. Its products enable safe and superior imagery for minimally invasive surgical procedures, operating independently of a power grid.